Neurodevelopmental Abnormalities in Children Associated with Maternal Use of Psychoactive Medication

Abstract

Background: Due to its negative effects on the unborn child and the mother as a consumer, pregnant women's intake of psychoactive substances has become a public health concern. Additionally, consuming these chemicals has been linked to several neurological development changes in children, including behavioral issues (such as attention deficit hyperactivity disorder and autism spectrum disorder), cognitive issues, and sensory and motor function changes. Objectives: To perform a thorough, comprehensive study of the neurodevelopmental problems in children linked to maternal drug use. Method: A search of the scientific literature on studies about neurodevelopmental abnormalities linked to maternal use of psychoactive medications during pregnancy and published in the previous ten years up to June 2022 was conducted from PubMed, Google Scholar, and Directory open access Journals. Results: The initial screening identified 380 articles. We excluded 50 unaccessible articles and 160 articles due to publication dates and study types; after that, 62 articles were also discarded because they were duplicates, and 68 were excluded because the information was irrelevant or systemic reviews, so we finally obtained 40 articles for full-text reading distributed as follows: 18 from PubMed, 12 from Directory Open Access Journal, and 10 from Google scholar

Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment

“…Currently, 13 medications are approved by the European Medicine Agency and Food and Drug Administration as disease-modifying treatments for MS, including IFN-1a (Avonex), IFN-1b (Betaseron or Extavia), glatiramer acetate (Copaxone), natalizumab (Tysabri), fingolimod (Gilenya), and dimethyl fumarate (Tecfi). [9,46–49] Numerous studies have examined the effect of clinical factors (relapses and the development of impairment) and/or MRI activity (defined as either new or expanding T2-lesions relative to baseline MRI scans or new or increased gadolinium-enhancing lesions) to identify disease-modifying treatment responders and non-responders. [50–54] IFN-Bs, glatiramer acetate therapy, teriflunomide, and dimethyl fumarate, are currently recommended by the Middle East and North Africa Committee for Treatment and Research in Multiple Sclerosis guidelines as first-line therapies for RRMS, and fingolimod is a suitable substitute for patients with needle phobia or other contraindications to the aforementioned drugs, for patients with a severely active illness (two or more debilitating relapses in a year associated with MRI abnormalities), fingolimod, natalizumab, or alemtuzumab are recommended as second-line treatments.…”

“…Immunoglobulin g (IgG) antibodies can also bind integrin α4β1 (very late antigen-4) and inhibit their migration. [ 9 ]…”

“…Immunoglobulin g (IgG) antibodies can also bind integrin α4β1 (very late antigen-4) and inhibit their migration. [9] T cells that are autoreactive spread into lymphatic tissues and undergo expansion. They ultimately enter the circulation after being triggered by sphingosine-1-phosphate.…”

“…Currently, 13 medications are approved by the European Medicine Agency and Food and Drug Administration as disease-modifying treatments for MS, including IFN-1a (Avonex), IFN-1b (Betaseron or Extavia), glatiramer acetate (Copaxone), natalizumab (Tysabri), fingolimod (Gilenya), and dimethyl fumarate (Tecfi). [9,[46][47][48][49] Numerous studies have Table 1 McDonald criteria for multiple sclerosis (MS). [20]…”

Pharmacological Properties of Spirulina Species: Hepatoprotective, Antioxidant and Anticancer Effects

“…And Spirulina sp. By studying the total phenolic content, flavonoids and phycobiliprotein, it was possible to conclude that the four species of cyanobacteria had antioxidant activity [41].…”